CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis.
The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physicians choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints studied including vital organ progression free survival (PFS), hematologic PFS, time to treatment failure and time to subsequent therapy were numerically higher in the NINLARO plus dexamethasone arm compared to the physicians choice arm. Takeda is committed to making data available to researchers to continue investigation of this disease. NINLARO is not approved as a treatment for AL amyloidosis.
AL amyloidosis is a rare condition, for which prognosis and patient outcomes are poor. Current treatments are often retrofitted from therapies used for multiple myeloma, said Angela Dispenzieri, MD, Mayo Clinic, and the trials principal investigator and lead author. For a Phase 3 study that did not meet its primary endpoint, this trial provides interesting information for this community and for future studies. Ongoing research and development to investigate potential treatment options for this underserved patient population is critical.
We look forward to the opportunity to share the data from the TOURMALINE-AL1 trial, said Phil Rowlands, Head of Oncology Clinical Research and Development, Takeda. We are confident that sharing our findings with the community will help encourage conversations around the need for continued research to address the needs that remain in this patient population.
There are serious unmet needs for people living with amyloidosis. AL amyloidosis is a progressive and fatal disease; many patients are diagnosed late, significantly impacting life expectancy. The challenges associated with developing drugs for this disease make continued research and development for treatment critical, said Isabelle Lousada, Founder and CEO of the Amyloidosis Research Consortium. The data from TOURMALINE-AL1 provide valuable insights to researchers as they select endpoints for future amyloidosis studies, and knowledge that will provide context in future drug reviews and approvals, ultimately aiding in providing treatment options for patients.
Primary Results from the Phase 3 TOURMALINE-AL1 Trial of Ixazomib-Dexamethasone Versus Physicians Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Saturday, December 7, 9:30 a.m., Orange County Convention Center, Hall E1.
Key findings, to be presented by Dr. Angela Dispenzieri, include:
About the TOURMALINE-AL1 Trial
TOURMALINE-AL1 (NCT01659658) is an international, randomized, controlled, open-label, multicenter, Phase 3 study, designed to determine whether NINLAROTM (ixazomib) in combination with dexamethasone improves hematologic response, two-year vital organ (heart or kidney) deterioration and mortality rate versus a physician's choice of a chemotherapy regimen in participants diagnosed with relapsed or refractory systemic light chain (AL) amyloidosis. 168 patients were enrolled and randomly selected to receive either NINLARO plus dexamethasone, or physicians choice of the following: dexamethasone plus melphalan; dexamethasone plus cyclophosphamide; dexamethasone plus thalidomide; dexamethasone plus lenalidomide; or dexamethasone alone. The discontinuation of the TOURMALINE-AL1 trial was announced in June 2019. For more information, please visit https://clinicaltrials.gov/ct2/show/NCT01659658.
About AL Amyloidosis
Primary AL amyloidosis is a condition that falls under the umbrella of plasma cell dyscrasias. AL amyloidosis arises from a clonal plasma cell that produces abnormal immunoglobulin light-chain fragments. These misfolded light-chains form insoluble fibrils that aggregate as amyloid deposits in organs and tissues throughout the body, ultimately leading to organ dysfunction and death. The most common organs affected are the kidneys, heart, liver, and autonomic or peripheral nerves.
There are currently no treatments approved for the treatment of AL amyloidosis.
About NINLAROTM (ixazomib) capsules
NINLARO (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings. NINLARO was first approved by the U.S. Food and Drug Administration (FDA) in November 2015 and is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is currently approved in more than 60 countries, including the United States, Japan and in the European Union, with more than 10 regulatory filings currently under review. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval.
The comprehensive ixazomib clinical development program, TOURMALINE, includes several ongoing pivotal trials, which together are investigating major multiple myeloma patient populations:
In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally.
NINLARO (ixazomib) capsules: Global Important Safety Information
SPECIAL WARNINGS AND PRECAUTIONSThrombocytopenia has been reported with NINLARO (28 percent vs. 14 percent in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines.
Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42 percent vs. 36 percent), constipation (34 percent vs. 25 percent), nausea (26 percent vs. 21 percent), and vomiting (22 percent vs. 11 percent), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care.
Peripheral neuropathy was reported with NINLARO (28 percent vs. 21 percent in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19 percent and 14 percent in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1 percent). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed.
Peripheral edema was reported with NINLARO (25 percent vs. 18 percent in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms.
Cutaneous reactions occurred in 19 percent of patients in the NINLARO regimen compared to 11 percent of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation.
Hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms.
Pregnancy- NINLARO can cause fetal harm. Advise male and female patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception.
Lactation- It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued.
SPECIAL PATIENT POPULATIONSHepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.
Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis.
DRUG INTERACTIONSCo-administration of strong CYP3A inducers with NINLARO is not recommended.
ADVERSE REACTIONSThe most frequently reported adverse reactions ( 20 percent) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42 percent vs. 36 percent), constipation (34 percent vs. 25 percent), thrombocytopenia (28 percent vs. 14 percent), peripheral neuropathy (28 percent vs. 21 percent), nausea (26 percent vs. 21 percent), peripheral edema (25 percent vs. 18 percent), vomiting (22 percent vs. 11 percent), and back pain (21 percent vs. 16 percent). Serious adverse reactions reported in 2 percent of patients included thrombocytopenia (2 percent) and diarrhea (2 percent). For each adverse reaction, one or more of the three drugs was discontinued in 1percent of patients in the NINLARO regimen.
For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/003844/WC500217620.pdf For US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf For Canada Product Monograph: http://www.takedacanada.com/ninlaropm
About Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit https://www.takeda.com
For the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takedas estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s), any of which may cause Takedas actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takedas results, performance, achievements, or financial position, see Item 3. Key InformationD. Risk Factors in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takedas future results.
- Pain treatment using human stem cells a success - News - The University of Sydney - January 24th, 2020
- PRP/Stem Cell Treatment Has Both Functional and Cosmetic Benefits - Haute Living - January 24th, 2020
- Daily briefing: First evidence of how stress turns hair grey - Nature.com - January 24th, 2020
- Gene Therapy for Sickle Cell Disease Receives Orphan Drug Designation - Monthly Prescribing Reference - January 24th, 2020
- High-Definition View of Diabetes-Related Proteins Obtained, Opening the Door to Future Treatments - SciTechDaily - January 24th, 2020
- Cynata Therapeutics to talk stem cell therapies at Proactive"s CEO Sessions - Proactive Investors Australia - January 24th, 2020
- Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of... - January 22nd, 2020
- Stem cell treatment off the table - Zululand Observer - January 22nd, 2020
- UK biotech PhoreMost to work with Otsuka on gene therapy projects - - pharmaphorum - January 22nd, 2020
- J&J wins another label expansion for Darzalex in Europe - PMLiVE - January 22nd, 2020
- Mayo woman raising funds for niece, 4, who is losing her sight from three different eye conditions - Extra.ie - January 22nd, 2020
- Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Predicted to Grow by 2028 with Competitive Situation and Business... - January 22nd, 2020
- Michael Schumacher health update: Neurosurgeon claims F1 legend 'nothing like we remember' - Express.co.uk - January 22nd, 2020
- Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position - GlobeNewswire - January 22nd, 2020
- Science Talk - Tell me more about telomeres: how 'basic' science can help us treat cancer - The Institute of Cancer Research - January 22nd, 2020
- The Clinical Trial that MS Patients Have Been Waiting For - Multiple Sclerosis News Today - January 19th, 2020
- Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) Dagoretti News - Dagoretti News - January 19th, 2020
- Libby Clegg health: Dancing On Ice star is registered blind - what is her condition? - Express - January 19th, 2020
- Stem Cell Therapy Market is Anticipated to Attain a Market Value of US$XX by the End of 2017 2025 - Fusion Science Academy - January 19th, 2020
- Zika Virus' Key into Brain Cells ID'd, Leveraged to Block Infection and Kill Cancer Cells - UC San Diego Health - January 17th, 2020
- Koepka Tied for 3rd in Abu Dhabi in Return From Knee Injury - The New York Times - January 17th, 2020
- Giraffe Will Go Through Risky Procedure At Cheyenne Mountain Zoo To Treat Ongoing Health Issues - CBS Denver - January 17th, 2020
- Novel form of cell-free therapy revealed by researchers - Drug Target Review - January 17th, 2020
- Choosing the Best Therapy for Patients with Chronic Lymphocytic Leukemia - Curetoday.com - January 17th, 2020
- Astellas, Adaptimmune to develop CAR-T & TCR T-cell therapies - BSA bureau - January 17th, 2020
- Melton parents of seriously ill little girl appeal for help to treat her - Melton Times - January 17th, 2020
- Study: Mutations in stem cells of young donors can be passed to recipients - STAT - January 15th, 2020
- Landmark Results for CaverStem Procedure Published in Journal of Translational Medicine to Create Paradigm Shift in Treatment of Erectile Dysfunction... - January 15th, 2020
- Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related... - January 15th, 2020
- Bluebird Bio taps ex-Celgene exec Heffron to lead its first gene therapy launch - FiercePharma - January 15th, 2020
- Celgene exec jumps to head bluebird bio ops in Europe, where its $1.8M gene therapy Zynteglo is now available - Endpoints News - January 15th, 2020
- Hemogenyx's CAR-T Cells are Effective Against AML in vitro - GuruFocus.com - January 15th, 2020
- Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or... - January 15th, 2020
- How Exosomes Could Lead To Stroke Recovery - Technology Networks - January 15th, 2020
- Koepka Ready to Get Back to Work After Nearly 3 Months Off - The New York Times - January 14th, 2020
- Astellas teams with Adaptimmune to create CAR-T, TCR therapies - FierceBiotech - January 14th, 2020
- FROM THE LABS: There is a new player in adult bone healing - Baylor College of Medicine News - January 14th, 2020
- Global Stem Cell Market Is Projected to Grow at a CAGR of 11.9% During the Forecast Period - Press Release - Digital Journal - January 14th, 2020
- Allogeneic Stem Cells Market Expected to Grow with a CAGR of 12% Due to New Product Approvals, 2020-2024 - ResearchAndMarkets.com - Business Wire - January 14th, 2020
- Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers -... - January 14th, 2020
- Stem cell agency indirectly boosted by national industry group - Capitol Weekly - January 13th, 2020
- Muscular dystrophy collaboration aims to correct muscle stem cells' DNA - Harvard Office of Technology Development - January 13th, 2020
- AstroRx Increased Ability to Perform Daily Functions in ALS Patients - ALS News Today - January 13th, 2020
- Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood - Yahoo Finance - January 13th, 2020
- Police Arrest 3 in Illegal Stem Cell Therapy Allegations - Tempo.co English - January 13th, 2020
- Stem Cell Therapy Market Competitive Analysis 2019-2027 - News ZMR - January 13th, 2020
- Editas Medicine and Sandhill Therapeutics, Inc. Announce Collaboration to Develop Engineered Cell Medicines to Treat Cancer | More News | News... - January 13th, 2020
- First ever progressive MS treatment approved for use by NHS in Scotland - The Scotsman - January 13th, 2020
- Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers - Yahoo... - January 13th, 2020
- The potential use of CRISPR to treat disease is gaining momentum - BioNews - January 13th, 2020
- At 16, Shes a Pioneer in the Fight to Cure Sickle Cell Disease - The New York Times - January 12th, 2020
- At 16, shes a pioneer in the fight to cure sickle cell disease at Boston Childrens - Boston.com - January 12th, 2020
- What is Mantle Cell Lymphoma and How Is It Treated? - Dana-Farber Cancer Institute - January 12th, 2020
- Doug Richards remembered - faribaultcountyregister.com | News, Sports, Information on the Blue Earth region - Faribault County Register - January 12th, 2020
- Kadimastem Finishes Treating Second Group of ALS Patients with AstroRx in Phase 1/2a Trial - ALS News Today - January 11th, 2020
- Jasper Therapeutics Announces Expansion of Series A Financing, Bringing Total Corporate Fundraising to More than $50 Million - Business Wire - January 11th, 2020
- Global Stem Cell Therapies Overview Report 2019: The Highs & Lows, Off-The-Shelf Solutions, New Technologies, and Safety, Efficacy & Logistical... - January 11th, 2020
- Q&A: Cancer Death Rates Are Falling Nationally. Here's What's Happening at UVA - University of Virginia - January 11th, 2020
- SVC112 molecule reduces effects of cancer stem cells with little toxicity - Drug Target Review - January 11th, 2020
- Helius Medical Technologies Awarded Pioneer Technology Development AwardBrain Mapping Foundation and Society for Brain Mapping Therapeutics name the... - January 11th, 2020
- ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies - Business Wire - January 11th, 2020
- Orgenesis adds UC Davis to its point-of-care network for developing cell, gene therapy products - Proactive Investors USA & Canada - January 11th, 2020
- Barry reveals the truth about Fiona on Fair City - RTE.ie - January 11th, 2020
- What will be the biggest scientific breakthrough of 2020? - Stuff.co.nz - January 11th, 2020
- Global Stem Cell Therapy Market 2020 by Company, Regions, Type and Application, Forecast to 2025 - BulletintheNews - January 11th, 2020
- Promethera Announces Initiation of Phase 2b DHELIVER Study of HepaStem in Patients with Acute-on-Chronic Liver Failure (ACLF) - Business Wire - January 9th, 2020
- Avacta and Daewoong Pharmaceutical Form Immunotherapy Focused Joint Venture - Technology Networks - January 9th, 2020
- Global Stem Cell Therapy Market Size is anticipated to grow at a strong CAGR by 2025 - Technology Magazine - January 9th, 2020
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - ReportsPioneer - January 9th, 2020
- Global Gene Therapy Market is Expected to Reach US$ 5,609.9 Million by 2027, Growing at an Estimated CAGR of 8.2% Over the Forecast Period as... - January 9th, 2020
- CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis - Associated Press - January 9th, 2020
- Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - Yahoo... - January 9th, 2020
- Kevin Nash on How His Health Is After Knee Replacement & Stem Cell Therapy, Why He Retired - LordsofPain.net - January 9th, 2020
- Stem Cell Alopecia Treatment Market 2019 Globally Expected to Drive Growth through 2024 - ReportsPioneer - January 9th, 2020
- Bone Therapeutics announces attendance at the 38th Annual J.P. Morgan Healthcare Conference - GlobeNewswire - January 9th, 2020
- Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - BioSpace - January 7th, 2020
- Gracell Initiates Investigational Study of the Technological Breakthrough TruUCAR Therapy for Relapsed or Refractory T-cell Malignancies - PRNewswire - January 7th, 2020
- Patrick Reed's latest controversy and the other things in golf that matter right now - ESPN - January 7th, 2020
- Diomics Corporation and University of California, Irvine Collaborate to Enable Cell Therapy Clinical Trial for Type 1 Diabetes - GlobeNewswire - January 7th, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Explores The Key Success Factors, And Business Opportunities Including Key... - January 7th, 2020